四方股份(601126.SH):啟航1號員工持股計劃第一批鎖定期屆滿
格隆匯9月23日丨四方股份(601126.SH)公佈,公司啟航1號員工持股計劃第一批解鎖的鎖定期於2021年9月23日屆滿。截止公吿披露日,公司啟航1號員工持股計劃證券賬户持有公司股票3173.95萬股,佔公司總股本的3.90%。
公司啟航1號員工持股計劃第一批解鎖的鎖定期屆滿後,將根據員工持股計劃的安排和市場情況等因素綜合考慮賣出股票的時機和數量。
該員工持股計劃的存續期為48個月,自公司公吿最後一筆標的股票過户至該員工持股計劃名下之日起算。該員工持股計劃在存續期屆滿時如未展期則自行終止,可經董事會審議批准提前終止或展期。存續期內,該員工持股計劃的股票全部出售完畢,可提前終止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.